Work

Phase I/II trial of glasdegib in patients with primary or secondary myelofibrosis.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.7061

Authors: Aaron Thomas Gerds, Tetsuzo Tauchi, Ellen K. Ritchie, Michael W.N. Deininger, Catriona HM Jamieson, Ruben A. Mesa, Mark L. Heaney, Norio Komatsu, Hironobu Minami, Yun Su, Mohammed Naveed Shaik, Xiaoxi Zhang, Christine DiRienzo, Mirjana Zeremski, Adrian Woolfson, Geoffrey Chan, Moshe Talpaz

Institutions: Tokyo Medical University, Weill Cornell Medicine, Oregon Health & Science University, Moores Cancer Center, Mayo Clinic, Mayo Clinic in Arizona, Columbia University Irving Medical Center, Juntendo University, Kobe University Hospital, Kobe University, Pfizer (United States), University of Michigan

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890501719

Cites:

Cited by: 2

Related to: 10